Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 08:05 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableUnknownINTERVENTIONAL

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

ClinicalTrials.gov · NCT02930265 · Registry updated: 2016-10-12

Condition / research focus: Ischemic Cardiomyopathy
Sponsor: Chinese PLA General Hospital
Countries with listed sites: China
Registry dates and results: Start: 2016-09. Completion: 2018-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Incretin Effect on the Immunological Phenotype

ClinicalTrials.gov · NCT01782261 · Registry updated: 2016-10-11

Condition / research focus: Type 1 Diabetes
Sponsor: Medical University of Graz
Countries with listed sites: Austria
Registry dates and results: Start: 2012-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
Saxagliptin (drug) — also listed as: Onglyza

Where the study takes place — 1 listed sites

Medical University Graz
Graz, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Effects of Beta-glucan on Energy Intake and Satiety

ClinicalTrials.gov · NCT02637388 · Registry updated: 2016-09-27

Condition / research focus: Obesity
Sponsor: Queen Margaret University
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2016-03. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oatwell28 Oatwell Original Powder (dietary_supplement)
Control Breakfast (dietary_supplement)

Where the study takes place — 1 listed sites

Queen Margaret University, Edinburgh
Musselburgh, East Lothain, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

ClinicalTrials.gov · NCT01733758 · Registry updated: 2016-09-22

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: GlaxoSmithKline
Countries with listed sites: Japan
Registry dates and results: Start: 2013-02. Completion: 2015-02 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Albiglutide 30 mg weekly (drug)
Albiglutide 50 mg weekly (drug)
Placebo (drug)
Liraglutide 0.9 mg daily (drug)

Where the study takes place — 74 listed sites

GSK Investigational Site
Aichi, Japan
Site recruitment: Not reported
GSK Investigational Site
Chiba, Japan
Site recruitment: Not reported
GSK Investigational Site
Ehime, Japan
Site recruitment: Not reported
GSK Investigational Site
Ehime, Japan
Site recruitment: Not reported
GSK Investigational Site
Ehime, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukushima, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukushima, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukushima, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukushima, Japan
Site recruitment: Not reported
GSK Investigational Site
Gunma, Japan
Site recruitment: Not reported
GSK Investigational Site
Gunma, Japan
Site recruitment: Not reported
GSK Investigational Site
Hiroshima, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hyōgo, Japan
Site recruitment: Not reported
GSK Investigational Site
Ibaraki, Japan
Site recruitment: Not reported
GSK Investigational Site
Ibaraki, Japan
Site recruitment: Not reported
GSK Investigational Site
Ibaraki, Japan
Site recruitment: Not reported
GSK Investigational Site
Kagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kagoshima, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kochi, Japan
Site recruitment: Not reported
GSK Investigational Site
Kumamoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Kumamoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Kumamoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Kyoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Kyoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Miyagi, Japan
Site recruitment: Not reported
GSK Investigational Site
Miyagi, Japan
Site recruitment: Not reported
GSK Investigational Site
Nagano, Japan
Site recruitment: Not reported
GSK Investigational Site
Nagano, Japan
Site recruitment: Not reported
GSK Investigational Site
Nagano, Japan
Site recruitment: Not reported
GSK Investigational Site
Nara, Japan
Site recruitment: Not reported
GSK Investigational Site
Okinawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Ōita, Japan
Site recruitment: Not reported
GSK Investigational Site
Ōita, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Shizuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Tochigi, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Yamaguchi, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

ClinicalTrials.gov · NCT02909933 · Registry updated: 2016-09-21

Condition / research focus: Polycystic Ovary Syndrome; Obesity
Sponsor: University Medical Centre Ljubljana
Countries with listed sites: Slovenia
Registry dates and results: Start: 2015-07. Completion: 2015-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: Victoza
metformin and liraglutide (drug) — also listed as: Glucophage and Victoza

Where the study takes place — 1 listed sites

University Medical Center Ljubljana
Ljubljana, Slovenia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Breakfast Intake and Satiety Hormones

ClinicalTrials.gov · NCT02497859 · Registry updated: 2016-09-16

Condition / research focus: Obesity
Sponsor: Texas Tech University
Countries with listed sites: United States
Registry dates and results: Start: 2015-09. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Egg Breakfast (EB) (behavioral)
Cereal Breakfast (CB) (behavioral)
Weight Loss Counseling (behavioral)
Weight Loss Diet (behavioral)

Where the study takes place — 1 listed sites

Texas Tech University - Department of Nutritional Sciences
Lubbock, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

ClinicalTrials.gov · NCT02535299 · Registry updated: 2016-09-13

Condition / research focus: GLP-1；Metformin；Telomere-telomerase System；Par-4
Sponsor: Third Military Medical University
Countries with listed sites: China
Registry dates and results: Start: 2016-06. Completion: 2019-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
Metformin (drug) — also listed as: Glucophage

Where the study takes place — 1 listed sites

Southwest Hospital of the Third Military Medical University
Chongqing, Chongqing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects

ClinicalTrials.gov · NCT02408705 · Registry updated: 2016-09-12

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Medical University of Graz
Countries with listed sites: Austria
Registry dates and results: Start: 2015-01. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
Placebo (drug)
Mixed Meal Tolerance Test with paracetamol (drug) — also listed as: MMTT

Where the study takes place — 1 listed sites

Medical University Graz
Graz, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes

ClinicalTrials.gov · NCT01684956 · Registry updated: 2016-09-07

Condition / research focus: Type 1 Diabetes
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2012-08. Completion: 2017-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Intradermal injection (procedure)
Subcutaneous injection (procedure)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1WithdrawnINTERVENTIONAL

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia

ClinicalTrials.gov · NCT02635243 · Registry updated: 2016-09-02

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Sanofi
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-04. Completion: 2016-11 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SAR438544 (drug)
r-glucagon (drug) — also listed as: GlucaGen® HypoKit
insulin (drug) — also listed as: Novolin® R

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

ClinicalTrials.gov · NCT02887625 · Registry updated: 2016-09-02

Condition / research focus: Type 2 Diabetes
Sponsor: Dr. Muhammad Abdulghani
Countries with listed sites: Qatar
Registry dates and results: Start: 2015-02. Completion: 2017-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pioglitazone plus exenatide (drug) — also listed as: actos and bydureon
insulin glargine and insulin aspart (drug) — also listed as: lantus

Where the study takes place — 1 listed sites

Hamad General Hospital
Doha, Qatar
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Liraglutide and Heart Failure in Type 2 Diabetes

ClinicalTrials.gov · NCT01425580 · Registry updated: 2016-09-01

Condition / research focus: Congestive Heart Failure; Type 2 Diabetes Mellitus
Sponsor: Thomas Nystrom
Countries with listed sites: Sweden
Registry dates and results: Start: 2012-01. Completion: 2016-08 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug)
glimepiride (drug)
Metformin (drug)

Where the study takes place — 2 listed sites

Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset
Stockholm, Sweden
Site recruitment: Not reported
Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB
Stockholm, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

ClinicalTrials.gov · NCT02625636 · Registry updated: 2016-08-23

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Sanofi
Countries with listed sites: United States
Registry dates and results: Start: 2015-12. Completion: 2016-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SAR438544 (drug)
placebo (drug)
r-glucagon (drug) — also listed as: GlucaGen® HypoKit, glucagon

Where the study takes place — 1 listed sites

Investigational Site Number 840001
Chula Vista, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes

ClinicalTrials.gov · NCT01153438 · Registry updated: 2016-08-17

Condition / research focus: Type 2 Diabetes; Obesity; Bariatric Surgery
Sponsor: University of Pennsylvania
Countries with listed sites: United States
Registry dates and results: Start: 2011-04. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Center for Weight and Eating Disorders, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

ClinicalTrials.gov · NCT02639130 · Registry updated: 2016-08-16

Condition / research focus: Type 2 Diabetes
Sponsor: Diabeteszentrum Bad Lauterberg im Harz
Countries with listed sites: Germany
Registry dates and results: Start: 2008-02. Completion: 2010-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exendin [9-39] (drug) — also listed as: (GLP-1 receptor antagonist)
Placebo (drug)

Where the study takes place — 1 listed sites

Diabeteszentrum Bad Lauterberg
Bad Lauterberg im Harz, Lower Saxony, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia

ClinicalTrials.gov · NCT02459938 · Registry updated: 2016-08-16

Condition / research focus: Hypoglycemia
Sponsor: Zosano Pharma Corporation
Countries with listed sites: Australia
Registry dates and results: Start: 2015-01. Completion: 2015-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon (ZP-Glucagon) (drug) — also listed as: glucagon
Glucagon (GlucaGen) (drug) — also listed as: glucagon

Where the study takes place — 1 listed sites

Nucleus Network
Melbourne, Victoria, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Glucagon Efficiency After High and Low Carbohydrate Diet

ClinicalTrials.gov · NCT02578498 · Registry updated: 2016-08-16

Condition / research focus: Type 1 Diabetes; Hypoglycemia
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2015-10. Completion: 2016-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

High carbohydrate intake (dietary_supplement)
Low carbohydrate intake (dietary_supplement)

Where the study takes place — 1 listed sites

Hvidovre University Hospital
Hvidovre, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Exercise, Glucose Kinetics, and the Incretin Effect

ClinicalTrials.gov · NCT01607931 · Registry updated: 2016-08-12

Condition / research focus: Type 2 Diabetes
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2013-01. Completion: 2016-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exercise (behavioral)

Where the study takes place — 1 listed sites

Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Antiproteinuric Effects of Liraglutide Treatment

ClinicalTrials.gov · NCT02545738 · Registry updated: 2016-08-10

Condition / research focus: Diabetic Kidney Disease
Sponsor: Steno Diabetes Center Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2015-04. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
placebo (drug)

Where the study takes place — 1 listed sites

Peter Rossing
Gentofte Municipality, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effect of LAPS-Exendin on Body Weight in Obese Population

ClinicalTrials.gov · NCT02075281 · Registry updated: 2016-08-09

Condition / research focus: Obesity
Sponsor: Hanmi Pharmaceutical Company Limited
Countries with listed sites: United States
Registry dates and results: Start: 2014-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HM11260C (biological)
Placebo (biological)

Where the study takes place — 1 listed sites

Hanmi pharmaceutical
Los Angeles, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 08:05 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableUnknownINTERVENTIONAL

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

ClinicalTrials.gov · NCT02930265 · Registry updated: 2016-10-12

Condition / research focus: Ischemic Cardiomyopathy
Sponsor: Chinese PLA General Hospital
Countries with listed sites: China
Registry dates and results: Start: 2016-09. Completion: 2018-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda

Where the study takes place — 1 listed sites

Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Incretin Effect on the Immunological Phenotype

ClinicalTrials.gov · NCT01782261 · Registry updated: 2016-10-11

Condition / research focus: Type 1 Diabetes
Sponsor: Medical University of Graz
Countries with listed sites: Austria
Registry dates and results: Start: 2012-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
Saxagliptin (drug) — also listed as: Onglyza

Where the study takes place — 1 listed sites

Medical University Graz
Graz, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Effects of Beta-glucan on Energy Intake and Satiety

ClinicalTrials.gov · NCT02637388 · Registry updated: 2016-09-27

Condition / research focus: Obesity
Sponsor: Queen Margaret University
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2016-03. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oatwell28 Oatwell Original Powder (dietary_supplement)
Control Breakfast (dietary_supplement)

Where the study takes place — 1 listed sites

Queen Margaret University, Edinburgh
Musselburgh, East Lothain, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

ClinicalTrials.gov · NCT01733758 · Registry updated: 2016-09-22

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: GlaxoSmithKline
Countries with listed sites: Japan
Registry dates and results: Start: 2013-02. Completion: 2015-02 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Albiglutide 30 mg weekly (drug)
Albiglutide 50 mg weekly (drug)
Placebo (drug)
Liraglutide 0.9 mg daily (drug)

Where the study takes place — 74 listed sites

GSK Investigational Site
Aichi, Japan
Site recruitment: Not reported
GSK Investigational Site
Chiba, Japan
Site recruitment: Not reported
GSK Investigational Site
Ehime, Japan
Site recruitment: Not reported
GSK Investigational Site
Ehime, Japan
Site recruitment: Not reported
GSK Investigational Site
Ehime, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukushima, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukushima, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukushima, Japan
Site recruitment: Not reported
GSK Investigational Site
Fukushima, Japan
Site recruitment: Not reported
GSK Investigational Site
Gunma, Japan
Site recruitment: Not reported
GSK Investigational Site
Gunma, Japan
Site recruitment: Not reported
GSK Investigational Site
Hiroshima, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hokkaido, Japan
Site recruitment: Not reported
GSK Investigational Site
Hyōgo, Japan
Site recruitment: Not reported
GSK Investigational Site
Ibaraki, Japan
Site recruitment: Not reported
GSK Investigational Site
Ibaraki, Japan
Site recruitment: Not reported
GSK Investigational Site
Ibaraki, Japan
Site recruitment: Not reported
GSK Investigational Site
Kagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kagoshima, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kanagawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Kochi, Japan
Site recruitment: Not reported
GSK Investigational Site
Kumamoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Kumamoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Kumamoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Kyoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Kyoto, Japan
Site recruitment: Not reported
GSK Investigational Site
Miyagi, Japan
Site recruitment: Not reported
GSK Investigational Site
Miyagi, Japan
Site recruitment: Not reported
GSK Investigational Site
Nagano, Japan
Site recruitment: Not reported
GSK Investigational Site
Nagano, Japan
Site recruitment: Not reported
GSK Investigational Site
Nagano, Japan
Site recruitment: Not reported
GSK Investigational Site
Nara, Japan
Site recruitment: Not reported
GSK Investigational Site
Okinawa, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Osaka, Japan
Site recruitment: Not reported
GSK Investigational Site
Ōita, Japan
Site recruitment: Not reported
GSK Investigational Site
Ōita, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Saitama, Japan
Site recruitment: Not reported
GSK Investigational Site
Shizuoka, Japan
Site recruitment: Not reported
GSK Investigational Site
Tochigi, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Tokyo, Japan
Site recruitment: Not reported
GSK Investigational Site
Yamaguchi, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

ClinicalTrials.gov · NCT02909933 · Registry updated: 2016-09-21

Condition / research focus: Polycystic Ovary Syndrome; Obesity
Sponsor: University Medical Centre Ljubljana
Countries with listed sites: Slovenia
Registry dates and results: Start: 2015-07. Completion: 2015-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug) — also listed as: Victoza
metformin and liraglutide (drug) — also listed as: Glucophage and Victoza

Where the study takes place — 1 listed sites

University Medical Center Ljubljana
Ljubljana, Slovenia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Breakfast Intake and Satiety Hormones

ClinicalTrials.gov · NCT02497859 · Registry updated: 2016-09-16

Condition / research focus: Obesity
Sponsor: Texas Tech University
Countries with listed sites: United States
Registry dates and results: Start: 2015-09. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Egg Breakfast (EB) (behavioral)
Cereal Breakfast (CB) (behavioral)
Weight Loss Counseling (behavioral)
Weight Loss Diet (behavioral)

Where the study takes place — 1 listed sites

Texas Tech University - Department of Nutritional Sciences
Lubbock, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

ClinicalTrials.gov · NCT02535299 · Registry updated: 2016-09-13

Condition / research focus: GLP-1；Metformin；Telomere-telomerase System；Par-4
Sponsor: Third Military Medical University
Countries with listed sites: China
Registry dates and results: Start: 2016-06. Completion: 2019-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
Metformin (drug) — also listed as: Glucophage

Where the study takes place — 1 listed sites

Southwest Hospital of the Third Military Medical University
Chongqing, Chongqing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects

ClinicalTrials.gov · NCT02408705 · Registry updated: 2016-09-12

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Medical University of Graz
Countries with listed sites: Austria
Registry dates and results: Start: 2015-01. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
Placebo (drug)
Mixed Meal Tolerance Test with paracetamol (drug) — also listed as: MMTT

Where the study takes place — 1 listed sites

Medical University Graz
Graz, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes

ClinicalTrials.gov · NCT01684956 · Registry updated: 2016-09-07

Condition / research focus: Type 1 Diabetes
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2012-08. Completion: 2017-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Intradermal injection (procedure)
Subcutaneous injection (procedure)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1WithdrawnINTERVENTIONAL

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia

ClinicalTrials.gov · NCT02635243 · Registry updated: 2016-09-02

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Sanofi
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-04. Completion: 2016-11 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SAR438544 (drug)
r-glucagon (drug) — also listed as: GlucaGen® HypoKit
insulin (drug) — also listed as: Novolin® R

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

ClinicalTrials.gov · NCT02887625 · Registry updated: 2016-09-02

Condition / research focus: Type 2 Diabetes
Sponsor: Dr. Muhammad Abdulghani
Countries with listed sites: Qatar
Registry dates and results: Start: 2015-02. Completion: 2017-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pioglitazone plus exenatide (drug) — also listed as: actos and bydureon
insulin glargine and insulin aspart (drug) — also listed as: lantus

Where the study takes place — 1 listed sites

Hamad General Hospital
Doha, Qatar
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Liraglutide and Heart Failure in Type 2 Diabetes

ClinicalTrials.gov · NCT01425580 · Registry updated: 2016-09-01

Condition / research focus: Congestive Heart Failure; Type 2 Diabetes Mellitus
Sponsor: Thomas Nystrom
Countries with listed sites: Sweden
Registry dates and results: Start: 2012-01. Completion: 2016-08 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug)
glimepiride (drug)
Metformin (drug)

Where the study takes place — 2 listed sites

Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset
Stockholm, Sweden
Site recruitment: Not reported
Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB
Stockholm, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

ClinicalTrials.gov · NCT02625636 · Registry updated: 2016-08-23

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Sanofi
Countries with listed sites: United States
Registry dates and results: Start: 2015-12. Completion: 2016-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SAR438544 (drug)
placebo (drug)
r-glucagon (drug) — also listed as: GlucaGen® HypoKit, glucagon

Where the study takes place — 1 listed sites

Investigational Site Number 840001
Chula Vista, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes

ClinicalTrials.gov · NCT01153438 · Registry updated: 2016-08-17

Condition / research focus: Type 2 Diabetes; Obesity; Bariatric Surgery
Sponsor: University of Pennsylvania
Countries with listed sites: United States
Registry dates and results: Start: 2011-04. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Center for Weight and Eating Disorders, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

ClinicalTrials.gov · NCT02639130 · Registry updated: 2016-08-16

Condition / research focus: Type 2 Diabetes
Sponsor: Diabeteszentrum Bad Lauterberg im Harz
Countries with listed sites: Germany
Registry dates and results: Start: 2008-02. Completion: 2010-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exendin [9-39] (drug) — also listed as: (GLP-1 receptor antagonist)
Placebo (drug)

Where the study takes place — 1 listed sites

Diabeteszentrum Bad Lauterberg
Bad Lauterberg im Harz, Lower Saxony, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia

ClinicalTrials.gov · NCT02459938 · Registry updated: 2016-08-16

Condition / research focus: Hypoglycemia
Sponsor: Zosano Pharma Corporation
Countries with listed sites: Australia
Registry dates and results: Start: 2015-01. Completion: 2015-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon (ZP-Glucagon) (drug) — also listed as: glucagon
Glucagon (GlucaGen) (drug) — also listed as: glucagon

Where the study takes place — 1 listed sites

Nucleus Network
Melbourne, Victoria, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Glucagon Efficiency After High and Low Carbohydrate Diet

ClinicalTrials.gov · NCT02578498 · Registry updated: 2016-08-16

Condition / research focus: Type 1 Diabetes; Hypoglycemia
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2015-10. Completion: 2016-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

High carbohydrate intake (dietary_supplement)
Low carbohydrate intake (dietary_supplement)

Where the study takes place — 1 listed sites

Hvidovre University Hospital
Hvidovre, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Exercise, Glucose Kinetics, and the Incretin Effect

ClinicalTrials.gov · NCT01607931 · Registry updated: 2016-08-12

Condition / research focus: Type 2 Diabetes
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2013-01. Completion: 2016-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exercise (behavioral)

Where the study takes place — 1 listed sites

Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Antiproteinuric Effects of Liraglutide Treatment

ClinicalTrials.gov · NCT02545738 · Registry updated: 2016-08-10

Condition / research focus: Diabetic Kidney Disease
Sponsor: Steno Diabetes Center Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2015-04. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza
placebo (drug)

Where the study takes place — 1 listed sites

Peter Rossing
Gentofte Municipality, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effect of LAPS-Exendin on Body Weight in Obese Population

ClinicalTrials.gov · NCT02075281 · Registry updated: 2016-08-09

Condition / research focus: Obesity
Sponsor: Hanmi Pharmaceutical Company Limited
Countries with listed sites: United States
Registry dates and results: Start: 2014-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HM11260C (biological)
Placebo (biological)

Where the study takes place — 1 listed sites

Hanmi pharmaceutical
Los Angeles, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →